Endocannabinoid Signaling in the Etiology and Treatment of Major Depressive Illness
Open accessThe DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Abstract
The purpose of this review is to examine human and preclinical data that are relevant to the following hypotheses. The first hypothesis is that deficient CB1R-mediated signaling results in symptoms that mimic those seen in depression. The second hypothesis is that activation of CB1R-mediated signaling results in behavioral, endocrine and other effects that are similar to those produced by currently used antidepressants. The third hypothesis is that conventional antidepressant therapies act through enhanced CB1R mediated signaling. Together the available data indicate that activators of CB1R signaling, particularly inhibitors of fatty acid amide hydrolase, should be considered for clinical trials for the treatment of depression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Neurotrophic Model for Stress-Related Mood Disorders
Duman, R. S., & Monteggia, L. M. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.02.013 · Cited by 3,375
Cannabinoid receptor localization in brain.
Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., de Costa, B. R., & Rice, K. C. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.5.1932 · Cited by 2,321 · cited 2×
“CB1R are very highly expressed in the brain, particularly in regions involved in motivated behavior and emotional processing [10].”
BackgroundHerkenham, M., Lynn, A., Johnson, M., Melvin, L., de Costa, B., & Rice, K. (1991) · The Journal of Neuroscience · doi:10.1523/jneurosci.11-02-00563.1991 · Cited by 2,159
Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides
Cravatt, B. F., Giang, D. K., Mayfield, S. P., Boger, D. L., Lerner, R. A., & Gilula, N. B. (1996) · Nature · doi:10.1038/384083a0 · Cited by 2,125 · cited 1×
“AEA is catabolized by two amidohydrolases: FAAH [27] and N-acylethanolamine-”
BackgroundHippocampal atrophy in recurrent major depression
Sheline, Y. I., Wang, P. W., Gado, M. H., Csernansky, J. G., & Vannier, M. W. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.9.3908 · Cited by 1,932 · cited 1×
“Hippocampal atrophy occurs in unmedicated individuals suffering from recurrent major depression [146] and it has been hypothesized, based on preclinical models of depression, that this is the result of reduced neurogenesis in the subgranular zone of the adult dentate gyrus [147].”
BackgroundStress, Depression, and Neuroplasticity: A Convergence of Mechanisms
Pittenger, C., & Duman, R. S. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301574 · Cited by 1,795 · cited 3×
“Chronic treatment with effective anti-depressant drugs, repeated ECT and voluntary exercise all increase neurogenesis in the hippocampus, evidence that reduced neurogenesis could contribute to depression [148].”
BackgroundToward a clinical model of suicidal behavior in psychiatric patients
Mann, J. J., Waternaux, C., Haas, G. L., & Malone, K. M. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.2.181 · Cited by 1,791 · cited 1×
“According to current theories regarding suicidal behaviour, risk of suicide is determined by both psychiatric illness and illness-independent, genetically mediated predisposition towards suicidal ideation [120].”
BackgroundThe endogenous cannabinoid system controls extinction of aversive memories
Marsicano, G., Wotjak, C. T., Azad, S. C., Bisogno, T., Rammes, G., Cascio, M. G., Hermann, H., Tang, J., Hofmann, C., Zieglgänsberger, W., et al. (2002) · Nature · doi:10.1038/nature00839 · Cited by 1,728 · cited 1×
“Reduced CB1R signaling and chronic CB1R antagonist treatment result in inappropriate extinction of aversive memories [132, 133] and increased likelihood that passive coping strategies will be used in the face of Hillard and Liu Page 10”
MethodWillner, P. (2005) · Neuropsychobiology · doi:10.1159/000087097 · Cited by 1,605 · cited 1×
“Chronic exposure to unpredictable stress (CUS) is used in rodents to evoke symptoms that mimic human depression, including anxiety, anhedonia, passive coping and learned helplessness [162].”
BackgroundNemeroff, C. B., Widerlöv, E., Bissette, G., Walléus, H., Karlsson, I., Eklund, K., Kilts, C. D., Loosen, P. T., & Vale, W. (1984) · Science · doi:10.1126/science.6334362 · Cited by 1,485 · cited 1×
“For example, corticotropin releasing factor (CRF) concentrations are increased in the CSF of depressed patients compared to controls [137].”
Background
Cited by
Lipids in Psychiatric Disorders and Preventive Medicine
Schneider, M., Levant, B., Reichel, M., Gulbins, E., Kornhuber, J., & Müller, C. P. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.06.002 · Cited by 175
Zhang, Z., Wang, W., Zhong, P., Liu, S. J., Long, J. Z., Zhao, L., Gao, H., Cravatt, B. F., & Liu, Q. (2015) · Hippocampus · doi:10.1002/hipo.22344 · Cited by 89
Rodrigues, R. S., Moreira, J. B., Mateus, J. M., Barateiro, A., Paulo, S. L., Vaz, S. H., Lourenço, D. M., Ribeiro, F. F., Soares, R., Loureiro-Campos, E., et al. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-02877-0 · Cited by 12
“Of note, MDD patients have lower levels of circulating endocannabinoids, suggesting that ECS hypoactivity may play a role in the pathophysiology of the disease [30].”
Metadata
- Authors
- Hillard, C., & Liu, Q.-S.
- Venue
- Current Pharmaceutical Design
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2014-06
- Volume
- 20
- Issue
- 23
- Pages
- 3795-3811
- ISSN
- 1381-6128 (ISSN-L)
- OpenAlex
- W2012757724
- Cited by
- 78
- References
- 67
- FWCI
- 3.46
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Endocannabinoid Signaling in the Etiology and Treatment of Major Depressive Illness. https://app.cochat.ai/papers/10.2174/13816128113196660735
- The paper
- Hillard, C., & Liu, Q.-S. (2014). Endocannabinoid Signaling in the Etiology and Treatment of Major Depressive Illness. Current Pharmaceutical Design. https://doi.org/10.2174/13816128113196660735
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.